- Home
- JRVR vs LENZ Comparison
JRVR vs LENZ Comparison
Compare JRVR & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JRVR | LENZ |
|---|---|---|
| Founded | 2002 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.2M | 278.4M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JRVR | LENZ |
|---|---|---|
| Price | $4.13 | $7.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $7.33 | ★ $44.00 |
| AVG Volume (30 Days) | 538.7K | ★ 868.0K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.64% | N/A |
| EPS Growth | ★ 125.82 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $687,614,000.00 | $19,088,000.00 |
| Revenue This Year | N/A | $50.42 |
| Revenue Next Year | $1.61 | $197.16 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.76 | $6.61 |
| 52 Week High | $7.20 | $50.19 |
Technical Indicators
Market Signals| Indicator | JRVR | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 27.71 | 39.49 |
| Support Level | $3.76 | N/A |
| Resistance Level | $5.61 | $10.42 |
| Average True Range (ATR) | 0.29 | 0.67 |
| MACD | -0.03 | -0.15 |
| Stochastic Oscillator | 14.40 | 23.68 |
Price Performance
Historical ComparisonAbout JRVR James River Group Holdings Ltd.
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.